Clinical Trial Update: A Study of YTS109 Cell Injection in Subjects With Relapsed/Refractory Autoimmune Hemolytic Anemia [Phase 1]

View source ↗

Summary

Phase 1 study evaluating YTS109 cell injections, an anti-CD19 STAR T-cell therapy, in patients with relapsed/refractory autoimmune hemolytic anemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autoimmune Hemolytic Anemia

Drugs mentioned

• Anti-CD19 STAR T-cell Therapy (CD19-targeted STAR T-cell therapy)
• YTS109 cell injection (YTS109 cell therapy)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Autoimmune Hemolytic Anemia, Anti-CD19 STAR T-cell Therapy | Phase 1 | Status: NOT_YET_RECRUITING